Efficacy and Safety of CsA+AVA in the Treatment of NSAA in the Elderly
Status:
Recruiting
Trial end date:
2025-08-01
Target enrollment:
Participant gender:
Summary
For elderly patients who cannot tolerate anti-thymocyte globulin (ATG) treatment, the
addition of avatrombopag (AVA), which has a slight adverse reaction, can theoretically
improve the hematological response rate in elderly patients with non-severe aplastic anemia
(NSAA) without significantly increasing adverse reactions. Based on this, this study treated
NSAA patients older than 60 with AVA combined with CsA to evaluate the hematological response
rate and safety of AVA in the elderly who could not tolerate ATG therapy.